Company IO Biotech, Inc.

Equities

IOBT

US4497781090

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-2.07%		-4.05%	-24.47%

Apr. 15	IO Biotech Announces Marjan Shamsaei as Senior Vice President	CI
Apr. 09	IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	CI

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Companyâs product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotechâs lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Number of employees: 68

Managers	Title	Age	Since
Mai-Britt Zocca FOU	Founder	56	14-11-30
Amy Sullivan DFI	Director of Finance/CFO	54	22-10-14
Eric Faulkner CTO	Chief Tech/Sci/R&D Officer	-	-
Qasim Ahmad CTO	Chief Tech/Sci/R&D Officer	-	-
Muhammad Al-Hajj CTO	Chief Tech/Sci/R&D Officer	53	21-04-30
Devin Smith CMP	Compliance Officer	56	23-01-22
Diane McDowell CTO	Chief Tech/Sci/R&D Officer	-	21-09-30
Brian Burkavage AUD	Comptroller/Controller/Auditor	-	20-12-31
Dan Mannix LAW	General Counsel	-	21-09-30

Members of the board	Title	Age	Since
David Smith BRD	Director/Board Member	64	22-02-28
K. Hirth CHM	Chairman	72	16-08-31
Kathleen Glaub BRD	Director/Board Member	70	18-04-30
Jack Nielsen BRD	Director/Board Member	60	20-12-31
Christian Ellebæk Elling BRD	Director/Board Member	55	15-11-30
Mai-Britt Zocca FOU	Founder	56	14-11-30
Heidi Hunter BRD	Director/Board Member	66	23-08-10
Helen Collins BRD	Director/Board Member	61	Nov. 08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	65,880,914	63,934,633 ( 97.05 %)	0	97.05 %

Name	Equities	%	Valuation
Lundbeckfond Invest A/S 21.18 %	13,950,686	21.18 %	24 M $
Kurma Partners SA 10.35 %	6,821,133	10.35 %	12 M $
Vivo Capital LLC 9.371 %	6,173,439	9.371 %	11 M $
Novo Holdings A/S (Investment Company) 7.723 %	5,088,258	7.723 %	9 M $
HBM Partners AG (Investment Management) 5.987 %	3,944,492	5.987 %	7 M $
Samsara Biocapital LLC 5.525 %	3,640,015	5.525 %	6 M $
PFM Health Sciences LP 3.554 %	2,341,107	3.554 %	4 M $
Morgan Stanley & Co. LLC 3.463 %	2,281,682	3.463 %	4 M $
Marshall Wace LLP 3.196 %	2,105,262	3.196 %	4 M $
Armistice Capital LLC 2.920 %	1,924,000	2.920 %	3 M $

IO Biotech, Inc.

Ole Maaløes Vej 3

2200, Copenhagen

http://www.iobiotech.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.42 USD

Average target price

8.75 USD

Spread / Average Target

+516.20%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IO BIOTECH, INC.	-24.47%	93.55M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research